公开(公告)号：US20240351988A1

公开(公告)日：2024-10-24

申请号：US18685378

申请日：2022-09-14

Applicant: Allianthera (Suzhou) Biopharmaceutical Co., Ltd. ,  Allianthera Boston Inc.

Inventor： Jinshan Chen ,  Rajiv Chopra ,  Jiamin Gu

IPC: C07D237/24 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/55 ,  A61K31/551 ,  A61K39/395 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D237/24 ,  A61K31/496 ,  A61K31/50 ,  A61K31/501 ,  A61K31/506 ,  A61K31/517 ,  A61K31/519 ,  A61K31/55 ,  A61K31/551 ,  A61K39/3955 ,  A61P35/00 ,  C07D401/12 ,  C07D401/14 ,  C07D403/04 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D405/14 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04

Abstract: Disclosed herein are compounds which can act modulators of the aryl hydrocarbon receptor (AHR). Further disclosed herein are methods for treating diseases and disorders, such as cancer and viral infections, using the compounds disclosed herein.

公开(公告)号：US20240317789A1

公开(公告)日：2024-09-26

申请号：US18580184

申请日：2022-08-05

Applicant: Allianthera (Suzhou) Biopharmaceutical Co., Ltd. ,  Allianthera Boston Inc.

Inventor： Jinshan Chen ,  Rajiv Chopra

IPC: C07H3/06 ,  A61K9/00 ,  A61K31/095 ,  A61K31/235 ,  A61K31/351 ,  A61K31/661 ,  A61P1/04 ,  C07C69/40 ,  C07C271/52 ,  C07C271/54 ,  C07C271/58 ,  C07C305/24 ,  C07C307/02 ,  C07F9/09 ,  C07F9/24

CPC classification number: C07H3/06 ,  A61K9/0014 ,  A61K9/0053 ,  A61K31/095 ,  A61K31/235 ,  A61K31/351 ,  A61K31/661 ,  A61P1/04 ,  C07C69/40 ,  C07C271/52 ,  C07C271/54 ,  C07C271/58 ,  C07C305/24 ,  C07C307/02 ,  C07F9/093 ,  C07F9/242

Abstract: Disclosed herein are prodrugs of tapinarof and pharmaceutical formulations comprising tarpinarof, such as oral formulations. Further disclosed herein are methods for treating diseases and disorders of the gastrointestinal tract, skin, eye, lung, and bone joints via the tapinarof prodrugs.